title: Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes.
abstract: BACKGROUND
  We sought to determine N-terminal pro-Brain Natriuretic Peptide (NTproBNP) levels among a population of individuals with type 2 diabetes, and to correlate these levels with diabetes medications and patient demographics.
  
  
  METHODS
  We analyzed data from 506 patients with type 2 diabetes. We compared NT-proBNP levels of these patients with those from the general population. We also sought to determine whether patients' NT-proBNP levels were correlated with diabetes medications, age, gender, creatinine, hemoglobin A1C levels, BMI, blood pressure, and lipid levels.
  
  
  RESULTS
  Increasing doses of sulfonylureas were associated with increasing levels of NT-proBNP. However, patients on combined sulfonylurea and metformin therapy had lower NT-proBNP levels than those on sulfonylureas alone. Neither thiazolidinediones nor insulin were associated with NT-proBNP levels. The majority of patients with type 2 diabetes had similar NT-proBNP levels compared to a reference group from the general population. In no age category did NT-proBNP levels differ significantly between men and women. Levels of NT-proBNP were positively associated with age (p<0.0001), systolic blood pressure (p<0.01) and creatinine levels (p<0.0001), and negatively associated with diastolic blood pressure (p<0.001). Levels of NT-proBNP were not associated with A1C, BMI, triglycerides, and high density lipoprotein (p=NS).
  
  
  CONCLUSIONS
  Levels of NT-proBNP are associated with increasing sulfonylurea dosage, age, blood pressure, and creatinine levels. There is unlikely to be clinically significant differences in NT-proBNP levels between patients with type 2 diabetes and a normal population.
authors.affiliation: Providence Health Care, St. Paul's Hospital, Vancouver BC, Canada. hught@istar.ca
authors.forename: Hugh D
authors.initials: HD
authors.lastname: Tildesley
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Aydin
authors.forename: Andrew
authors.initials: A
authors.lastname: Ignaszewski
authors.forename: Jason A
authors.initials: JA
authors.lastname: Strelzow
authors.forename: Eugenia
authors.initials: E
authors.lastname: Yu
authors.forename: Greg
authors.initials: G
authors.lastname: Bondy
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D016022:Case-Control Studies; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000378:metabolism; D010446:Peptide Fragments / Q000097:blood* / Q000378:metabolism; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D012737:Sex Factors; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D010446:Peptide Fragments; D013453:Sulfonylurea Compounds; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain